Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
L286934-5mg
|
5mg |
3
|
$124.90
|
|
|
L286934-10mg
|
10mg |
3
|
$191.90
|
|
|
L286934-25mg
|
25mg |
3
|
$431.90
|
|
|
L286934-50mg
|
50mg |
1
|
$670.90
|
|
|
L286934-100mg
|
100mg |
2
|
$1,207.90
|
|
|
L286934-250mg
|
250mg |
2
|
$2,716.90
|
|
Potent, selective BTK inhibitor
| Synonyms | AKOS028108222 | alpha-Cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide | KBio3_001038 | HMS3370M16 | L0309 | 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide | Bio2_000450 | KBio2_000579 | KBio2_005715 | KBio3_001037 | Q27166836 | KBioG |
|---|---|
| Specifications & Purity | ≥98%(HPLC) |
| Biochemical and Physiological Mechanisms | Potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits recombinant BTK with an IC50value of 2.5μM and has no activity on other protein kinases ( including JAK1, JAK3, HCK, EGFR kinase and insulin receptor kinase) at concentrations of u |
| Storage Temp | Protected from light,Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Product description: A potent, cell-permeable, reversible, substrate competitive, and specific inhibitor of Bruton’s Tyrosine Kinase (BTK; IC50 = 17.2 µM for human BTK in vitro and IC50 = 2.5 µM for recombinant BTK). Also inhibits Polo-like kinase in an ATP-competitive manner (IC50 = 10 µM and 61 µM for Plx1 and Plk3, respectively), and displays antitumor properties. Does not affect the enzymatic activity of other protein tyrosine kinases, including EGFR, HCK, IRK JAK1, and JAK3 even at concentrations of 278 µM. Enhances the chemosensitivity of BTK-positive B-lineage leukemia cells to ceramide- and vincristine-induced apoptosis. A potent, cell-permeable, reversible, substrate competitive, and specific inhibitor of Bruton′s tyrosine kinase (BTK; IC50 = 17.2 µM for human BTK in vitro and IC50 = 2.5 µM for recombinant BTK). Also inhibits Polo-like kinase in an ATP-competitive manner (IC50 = 10 µM and 61 µM for Plx1 and Plk3, respectively), and displays antitumor properties. Does not affect the enzymatic activity of other protein tyrosine kinases, including EGFR, HCK, IRK JAK1, and JAK3 even at concentrations of 278 µM. Enhances the chemosensitivity of BTK-positive B-lineage leukemia cells to ceramide- and vincristine-induced apoptosis. |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Benzene and substituted derivatives |
| Subclass | Anilides |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Anilides |
| Alternative Parents | N-arylamides Bromobenzenes Aryl bromides Vinylogous acids Secondary carboxylic acid amides Nitriles Enols Organopnictogen compounds Organobromides Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Aromatic homomonocyclic compounds |
| Substituents | Anilide - N-arylamide - Bromobenzene - Halobenzene - Aryl bromide - Aryl halide - Vinylogous acid - Carboxamide group - Secondary carboxylic acid amide - Carboxylic acid derivative - Enol - Carbonitrile - Nitrile - Organopnictogen compound - Organic oxygen compound - Hydrocarbon derivative - Organic nitrogen compound - Organic oxide - Carbonyl group - Organohalogen compound - Organobromide - Organonitrogen compound - Organooxygen compound - Aromatic homomonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution. |
| External Descriptors | Not available |
|
|
|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 488201704 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488201704 |
| IUPAC Name | 2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide |
| INCHI | InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17) |
| InChIKey | UVSVTDVJQAJIFG-UHFFFAOYSA-N |
| Smiles | CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O |
| Isomeric SMILES | CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O |
| Molecular Weight | 360 |
| Reaxy-Rn | 10678941 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=10678941&ln= |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 | |
| Certificate of Analysis | Aug 15, 2022 | L286934 |
| Solubility | Solvent:DMSO, Max Conc. mg/mL: 36, Max Conc. mM: 100 |
|---|---|
| Sensitivity | light & heat sensitive |
| Molecular Weight | 360.000 g/mol |
| XLogP3 | 3.800 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 359.893 Da |
| Monoisotopic Mass | 357.895 Da |
| Topological Polar Surface Area | 73.100 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 386.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 1 |
| The total count of all stereochemical bonds | 1 |
| Covalently-Bonded Unit Count | 1 |